These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 30417521)

  • 1. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
    Brar N; Lawrence L; Fung E; Zehnder JL; Greenberg PL; Mannis GN; Zhang TY; Gratzinger D; Oak J; Silva O; Kurzer J; Tan B; Menke JR; Fernandez-Pol S
    Am J Clin Pathol; 2024 Sep; 162(3):269-281. PubMed ID: 38643353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype].
    Liu YR; Lai YY; Chang Y; Ruan GR; Qin YZ; Wang YZ; Zhu HH; Shi HX; Jiang B; Jiang H; Jiang Q; Hao L; Li JL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1385-9. PubMed ID: 24370016
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Forghieri F; Nasillo V; Paolini A; Bettelli F; Pioli V; Giusti D; Gilioli A; Colasante C; Acquaviva G; Riva G; Barozzi P; Maffei R; Potenza L; Marasca R; Fozza C; Tagliafico E; Trenti T; Comoli P; Longo G; Luppi M
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I diagnose and treat NPM1-mutated AML.
    Falini B; Brunetti L; Martelli MP
    Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
    Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
    Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia.
    Mannelli F; Ponziani V; Bonetti MI; Bencini S; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Rondelli T; Benelli M; Caporale R; Grazia Gelli AM; Peruzzi B; Longo G; Bosi A
    Exp Hematol; 2015 Oct; 43(10):869-879.e22. PubMed ID: 26101160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
    Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
    Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
    Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry.
    Fang H; Wang SA; Hu S; Konoplev SN; Mo H; Liu W; Zuo Z; Xu J; Jorgensen JL; Yin CC; El Hussein S; Jelloul FZ; Tang Z; Medeiros LJ; Wang W
    Cytometry B Clin Cytom; 2022 Jul; 102(4):283-291. PubMed ID: 35716019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
    Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
    JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.